Aug 1, 2022 · PLGA-based NPs can be used for a variety of cancer therapies including tumor-targeted drug delivery, gene therapy, hyperthermia, and photodynamic therapy.

Nanoparticles based on single-component synthetic polymers, such as poly (lactic acid-co-glycolic acid) (PLGA), have been extensively studied for antitumor drug delivery and adjuvant therapy …

Mar 3, 2020 · To address these challenges, we have designed hybrid NPs that consist of a polylactic-co-glycolic acid (PLGA) core ‘wrapped’ with a cross-linked bovine serum albumin …

In this study, we developed Poly (lactic-co-glycolic acid) nanoparticles (PLGA-NPs) containing the chemotherapeutic drug Docetaxel, functionalized with a cyclic RGD tripeptide to allow the …

Jul 19, 2023 · In this protocol, we describe the preparation and physicochemical and biological characterization of choline carboxylate IL-coated polymeric NPs.

While larger-sized PLGA NPs (>300 nm) are generally associated with increased drug loading capacity, PLGA NPs with a relatively small size range (50 to 100 nm) demonstrate longer …

Nov 2, 2018 · Poly (lactic-co-glycolic acid) (PLGA)-based materials are frequently used in such setups. This review article gives an overview of the properties of previously reported PLGA …

Aug 4, 2022 · Employing PLGA NPs to establish a large range of size-controlled drug delivery systems and achieve size-selective drug delivery targeting remains a challenge for therapeutic …

Jul 9, 2022 · PLGA-NPs showed a controlled in vitro cyclosporine release profile for 23 days at a constant rate (37 μg/day), good in vitro hemocompatibility, higher intestinal uptake and relative …

Poly (lactic-co-glycolic acid) (PLGA) is one of the most effective biodegradable polymeric nanoparticles (NPs). It has been approved by the US FDA to use in drug delivery systems due …